Calidi Biotherapeutics (Calidi Biotherapeutics) Total Stockholders Equity : $-14.57 Mil (As of Mar. 2024)

View and export this data going back to 2023. Start your Free Trial

What is Calidi Biotherapeutics Total Stockholders Equity?

Calidi Biotherapeutics's Total Stockholders Equity for the quarter that ended in Mar. 2024 was $-14.57 Mil. It refers to the net assets owned by shareholders. It does not include minority interest.

Total Stockholders Equity is used to calculate Book Value per Share. Calidi Biotherapeutics's Book Value per Share for the quarter that ended in Mar. 2024 was $-0.41. The ratio of a company's debt over equity can be used to measure how leveraged this company is. Calidi Biotherapeutics's Debt-to-Equity for the quarter that ended in Mar. 2024 was -0.80.

Calidi Biotherapeutics Total Stockholders Equity Historical Data

The historical data trend for Calidi Biotherapeutics's Total Stockholders Equity can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Calidi Biotherapeutics Total Stockholders Equity Chart

Calidi Biotherapeutics Annual Data

Trend

Dec20

Dec21

Dec22

Dec23

Total Stockholders Equity

-22.48

-31.61

-50.44

-8.24

Calidi Biotherapeutics Quarterly Data
	Dec20	Sep21	Dec21	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
Total Stockholders Equity	Get a 7-Day Free Trial					-	-63.71	-1.09	-8.24	-14.57

Calidi Biotherapeutics (AMEX:CLDI) Total Stockholders Equity Explanation

1. Total Stockholders Equity is used to calculate Book Value per Share.

Calidi Biotherapeutics's Book Value per Share for the quarter that ended in Mar. 2024 is

Book Value per Share	=	(Total Stockholders Equity	-	Preferred Stock)	/	Shares Outstanding (EOP)
	=	(-14.573	-	0)	/	35.7268
	=	-0.41

2. The ratio of a company's debt over equity can be used to measure how leveraged this company is.

Calidi Biotherapeutics's Debt-to-Equity for the quarter that ended in Mar. 2024 is

Debt-to-Equity	=	Total Debt			/	Total Stockholders Equity
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Total Stockholders Equity
	=	(5.385	+	6.328)	/	-14.573
	=	-0.80

Calidi Biotherapeutics Total Stockholders Equity Related Terms

Thank you for viewing the detailed overview of Calidi Biotherapeutics's Total Stockholders Equity provided by GuruFocus.com. Please click on the following links to see related term pages.

Calidi Biotherapeutics (Calidi Biotherapeutics) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Calidi Biotherapeutics Inc (AMEX:CLDI) » Definitions » Total Stockholders Equity

Comparable Companies

Traded in Other Exchanges

N/A

Address

11011 North Torrey Pines Road, Suite 200, La Jolla, CA, USA, 92037

Website

https://www.calidibio.com

Calidi Biotherapeutics Inc is a clinical stage immuno-oncology company pioneering the development and commercialization of novel, potent and efficient stem cell-based platforms for delivery and potentiation of oncolytic viruses for the treatment of cancer.

Calidi Biotherapeutics (Calidi Biotherapeutics) Headlines

From GuruFocus

Calidi Biotherapeutics and Unusual Machines Interviews to Air on the RedChip Small Stocks, Big Mone(TM) Show on Bloomberg TV

By ACCESSWIRE • 05-17-2024